| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/28/2014 | CA2662613C Compositions and methods relating to glucagon receptor antibodies |
| 01/28/2014 | CA2654522C Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient |
| 01/28/2014 | CA2628333C Influenza vaccines extemporaneously adsorbed to aluminium adjuvants |
| 01/28/2014 | CA2616877C Systems and methods for manufacturing liposomes |
| 01/28/2014 | CA2611954C Dengue serotype 2 attenuated strain |
| 01/28/2014 | CA2599734C Humanized l243 antibodies |
| 01/28/2014 | CA2540521C Anti-nik antibodies and uses thereof |
| 01/28/2014 | CA2520382C Lupus antibodies for passive immunotherapy of hiv/aids |
| 01/28/2014 | CA2510315C Antibodies against gpr64 and uses thereof |
| 01/28/2014 | CA2492295C Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion |
| 01/28/2014 | CA2481799C Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
| 01/28/2014 | CA2430039C Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| 01/23/2014 | WO2014015287A2 Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains |
| 01/23/2014 | WO2014015242A1 Measles viruses with reduced susceptibility to neutralization |
| 01/23/2014 | WO2014015148A1 Human btnl3 proteins, nucleic acids, and antibodies and uses thereof |
| 01/23/2014 | WO2014015133A1 Treatment of osteoarthritis using il-20 antagonists |
| 01/23/2014 | WO2014015116A2 Novel arterivirus protein and expression mechanisms |
| 01/23/2014 | WO2014014897A2 Immunoglobulin-binding human mycoplasma antigens and methods of use thereof |
| 01/23/2014 | WO2014014821A1 Antibody specific for cd22 and methods of use thereof |
| 01/23/2014 | WO2014014819A2 Methods of treating glucose metabolism disorders |
| 01/23/2014 | WO2014014816A2 Methods of treating glucose metabolism disorders |
| 01/23/2014 | WO2014014726A1 Attenuated swine influenza vaccines and methods of making and use thereof |
| 01/23/2014 | WO2014014725A1 Method of providing protective immunity against heterologous leptospira strains |
| 01/23/2014 | WO2014014670A1 Synthetic oligosaccharides for p. aeruginosa vaccine |
| 01/23/2014 | WO2014013231A1 Materials and methods for treating pten mutated or deficient cancer |
| 01/23/2014 | WO2014013123A1 Composition for the intradermal administration of allergoids |
| 01/23/2014 | WO2014013075A2 Antibodies to highly conserved targets |
| 01/23/2014 | WO2014013036A1 Inhibitors of the cd95 signaling pathway for treatment of mds |
| 01/23/2014 | WO2014013019A1 Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation |
| 01/23/2014 | WO2014013014A1 Jak inhibitors for activation of epidermal stem cell populations |
| 01/23/2014 | WO2014012479A1 Compounds for targeted immunotherapy |
| 01/23/2014 | WO2014012165A1 Anti-siglec-15 antibodies |
| 01/23/2014 | WO2013169886A9 Anti-pcsk9 antibodies and use thereof |
| 01/23/2014 | WO2013166183A3 Replikin sequences and their antibodies, therapeutics and vaccines against prion and neurodegenerative disorders |
| 01/23/2014 | WO2013142377A3 Modified marek's disease virus, and vaccines made therefrom |
| 01/23/2014 | US20140023699 Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration |
| 01/23/2014 | US20140023685 Bivalent vaccine for marine fish and method for making the same |
| 01/23/2014 | US20140023684 Vaccine Against Pasteurellaceae |
| 01/23/2014 | US20140023683 Identification of transmitted hepatitis c virus (hcv) genomes by single genome amplification |
| 01/23/2014 | US20140023682 Cancer Inhibiting Agent, Antibody Production Enhancing Agent, And Therapeutic Agent For Hepatitis |
| 01/23/2014 | US20140023681 Attenuated Swine Influenza Vaccines and Methods of Making and Use Thereof |
| 01/23/2014 | US20140023680 Influenza hemagglutinin and neuraminidase variants |
| 01/23/2014 | US20140023678 Method of Providing Protective Immunity against Heterologous Leptospira Strains |
| 01/23/2014 | US20140023673 Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
| 01/23/2014 | US20140023671 Tomm34 peptides and vaccines including the same |
| 01/23/2014 | US20140023670 Cancer vaccine composition |
| 01/23/2014 | US20140023669 Use of a hypoallergenic cereal composition for inducing specific oral tolerance |
| 01/23/2014 | US20140023663 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase |
| 01/23/2014 | US20140023661 Combination therapy |
| 01/23/2014 | US20140023658 Regulating il-4 and il-3 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor |
| 01/23/2014 | US20140023655 Formulations with reduced viscosity |
| 01/23/2014 | US20140023654 Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
| 01/23/2014 | US20140023652 Methods and compositions based on shiga toxin type 1 protein |
| 01/23/2014 | US20140023650 Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
| 01/23/2014 | US20140023647 Method for treating solid tumors |
| 01/23/2014 | US20140023646 Compositions and Methods for Treating Viral Infection |
| 01/23/2014 | US20140023643 N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| 01/23/2014 | US20140023640 Method to identify a pateint with an increased likelihood of responding to an anti-cancer therapy |
| 01/23/2014 | US20140023639 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| 01/23/2014 | US20140023589 Frmd4a antagonists and their uses |
| 01/23/2014 | DE112011104956T5 Mycobakterium Brumae Zellwandextrakte, die in der Therapie von oberflächlichem Blasenkrebs verwendet werden können Brumae mycobacterium cell wall extracts that can be used in the therapy of superficial bladder cancer |
| 01/23/2014 | CA2876787A1 Inhibitors of the cd95 signaling pathway for treatment of mds |
| 01/23/2014 | CA2876517A1 Anti-siglec-15 antibodies |
| 01/23/2014 | CA2875486A1 Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation |
| 01/22/2014 | EP2687593A1 Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| 01/22/2014 | EP2687541A1 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides |
| 01/22/2014 | EP2687540A1 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides |
| 01/22/2014 | EP2687232A1 Methods of treating systemic lupus erythematosus |
| 01/22/2014 | EP2687231A1 Composition for treatment and diagnosis of pancreatic cancer |
| 01/22/2014 | EP2687230A1 Allergen peptide fragments and use thereof |
| 01/22/2014 | EP2687229A1 Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses |
| 01/22/2014 | EP2687228A2 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| 01/22/2014 | EP2687227A1 Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response |
| 01/22/2014 | EP2687203A1 Emulsified composition for dilution and cancer vaccine composition |
| 01/22/2014 | EP2687202A1 Subcutaneous anti-her2 antibody formulation |
| 01/22/2014 | EP2686339A1 Novel oprf/i fusion proteins, their preparation and use |
| 01/22/2014 | EP2686020A1 Re-directed immunotherapy |
| 01/22/2014 | EP2686016A1 Antibody recognizing n-domain of midkine |
| 01/22/2014 | EP2686015A2 Overcoming resistance to erbb pathway inhibitors |
| 01/22/2014 | EP2686014A1 Uses of a dual v region antibody-like protein |
| 01/22/2014 | EP2686013A1 Treatment for peanut allergy |
| 01/22/2014 | EP2686012A2 Equine rhinitis vaccine |
| 01/22/2014 | EP2686011A2 IPN Vaccine |
| 01/22/2014 | EP2686010A2 Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
| 01/22/2014 | EP2686009A1 Method for preparing multiple antigen glycopeptide carbohydrate conjugates |
| 01/22/2014 | EP2686008A1 Compositions and methods for inhibiting tumor development caused by chemotherapy induced senescence |
| 01/22/2014 | EP2685995A1 Yeast-brachyury immunotherapeutic compositions |
| 01/22/2014 | CN103534593A The use anti-CXCL16 and anti- CXCR6 antibodies for the treatment or detecting cancer |
| 01/22/2014 | CN103534351A Nucleic acid construct containing nucleic acid derived from genotype 1b HCV genome, HCV genome-replicating cells transfected with same, and method for producing infectious HCV particles |
| 01/22/2014 | CN103534347A Production of low fucose antibodies in H4-II-E rat cells |
| 01/22/2014 | CN103534272A Antibody specifically recognising transferrin receptor |
| 01/22/2014 | CN103534271A Monoclonal antibody having immunosuppressive activity or fragment to which antigen thereof is bonded |
| 01/22/2014 | CN103534270A Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof |
| 01/22/2014 | CN103534233A Heterobifunctional esters for use in labeling target molecules |
| 01/22/2014 | CN103533961A Method for egfr directed combination treatment of cancer |
| 01/22/2014 | CN103533960A C-kit antibodies and uses thereof |
| 01/22/2014 | CN103533959A Formulation for anti-Alpha4Beta7 antibody |
| 01/22/2014 | CN103533958A Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications |
| 01/22/2014 | CN103533957A Humanized antibodies to LIV-1 and use of same to treat cancer |
| 01/22/2014 | CN103533956A Compositions and methods |